Article Title: Chinese biotech Minghui raises $131M to advance its PD-1xVEGF bispecific
Publication Date: August 07, 2025
In a move that brings the growing power of Chinese biotech into focus once again, Minghui Pharmaceutical, headquartered in Shanghai, has secured an impressive $131 million in pre-IPO financing. This news was made public by the company on August 7, 2025. The biotech firm, already generating considerable interest among blue-chip investors, is working on the development of PD-1xVEGF bispecifics and other antibody-drug conjugates (ADC).
This substantial funding is expected to provide Minghui with a significant boost, enabling the firm to drive its innovative PD-1xVEGF bispecifics and ADCs through critical development phases. Both these therapeutic classes have been attracting increasing attention due to their potential to more effectively target disease pathways, in comparison to single-targeting therapies. This funding might also allow the biotech to enhance its drug pipeline and, quite possibly, speed up its overall developmental timeline.
Investors are likely to be closely tracking Minghui’s use of this sizeable fund. The PD-1xVEGF bispecific that Minghui is working on may offer significant commercial potential, given the increasing focus on ADCs and the growing prominence of bispecifics in the oncology sector. As continued breakthroughs redefine the oncology market, firms like Minghui are worth keeping an eye on.
Join us at Industry Informant to stay up-to-date with the latest movements in the global biotech market. We provide clear, precise and timely analyses to help investors, executives, and decision-makers navigate the ever-evolving landscape. With our data-driven insights, our readers gain a strategic edge in the fast-paced world of biotechnology investments.
